Subscribe for free to the America First Report newsletter.
Tom Cruise shines as America’s last true movie star in the apolitical and wildly entertaining ‘Mission: Impossible — Dead Reckoning.’ Share
The seventh installment in the “Mission: Impossible” franchise is out, and it’s shaping up to be another behemoth at the box office. What’s particularly interesting about this franchise is how, unlike almost every other intellectual property, it’s mostly gotten better over time. Usually, the opposite is true. Much of the juice driving this is none other than Tom Cruise himself, the seemingly ageless wonder who continues to defy expectations.
The other and maybe more important part of this magic formula is writer and director Christopher Macquarrie. Since 2008, he and Cruise have collaborated on 11 projects for a combined box office return of over $5 billion. Their projects’ combined earnings are comparable to entire movie franchises. Their earnings rank between “Avatar” and “Despicable Me” for the biggest box […]
Excerpt Sourced From: thefederalist.com
What Would You Do If Pharmacies Couldn’t Provide You With Crucial Medications or Antibiotics?
The medication supply chain from China and India is more fragile than ever since Covid. The US is not equipped to handle our pharmaceutical needs. We’ve already seen shortages with antibiotics and other medications in recent months and pharmaceutical challenges are becoming more frequent today.
Our partners at Jase Medical offer a simple solution for Americans to be prepared in case things go south. Their “Jase Case” gives Americans emergency antibiotics they can store away while their “Jase Daily” offers a wide array of prescription drugs to treat the ailments most common to Americans.
They do this through a process that embraces medical freedom. Their secure online form allows board-certified physicians to prescribe the needed drugs. They are then delivered directly to the customer from their pharmacy network. The physicians are available to answer treatment related questions.
